Neurotrope Tackles Alzheimer’s Disease With Novel Mechanism: Jason Napodano, CFA See note please

The Founder and director of this company is a dear friend and e-pal….Dr. J. Abeles


  • Neurotrope, Inc. is developing therapeutics for neurodegenerative diseases such as Alzheimer’s Disease (AD).
  • The company’s lead compound, bryostatin-1, is a natural compound isolated from a tiny, ocean dwelling organism.
  • Bryostatin-1 activates protein kinase C (PKC) and represents a novel treatment option for AD that is supported by extensive preclinical data.
  • The company is also developing an AD diagnostic test with early results showing sensitivity (correctly diagnosing AD) ≥ 97% and specificity (correctly identifying individuals without AD) ≥ 96%.
  • Neurotrope has a basic market capitalization of only $14 million, with $10+ million in cash in the bank and data from a Phase 2a study coming in early 2015.

Neurotrope, Inc (OTCQB:NTRP) is seeking to commercialize technology developed at and exclusively licensed from the Blanchette Rockefeller Neurosciences Institute (BRNI) for therapeutic and diagnostic applications in Alzheimer’s Disease (AD) and other neurodegenerative disorders. We believe the company has a promising technology, is highly undervalued, and well-funded to show initial proof-of-concept for its lead development candidate in early 2015.

…Alzheimer’s Disease…

Alzheimer’s disease (AD) is the most common form of dementia in older adults. The disease is named after Dr. Alois Alzheimer, who identified the first case in a 50-year-old woman named Auguste Deter in 1902. Dr. Alzheimer followed her case until her death in 1906, at which point he first publicly reported on it (Alzheimer, 1907).

The most common early symptom of AD is a gradually worsening ability to remember new information. This is due to neurons associated with forming new memories dying off first. As neurons in other parts of the brain die, individuals experience different symptoms, which include:

  • Memory loss that disrupts daily life
  • Inability to plan or solve problems
  • Difficulty completing familiar tasks
  • Confusion with location and time
  • Difficulty with visual images and spatial relationships
  • Problems with words in speaking or writing
  • Withdrawal from social activities
  • Changes in mood, including apathy and depression

Comments are closed.